Arcellx: Anito-Cel With D-Domain Differentiation Looks To Capture R/R MM Market

Company Overview - Arcellx, Inc. (NASDAQ: ACLX) is advancing its lead CAR-T cell therapy, anitocabtagene Autoleucel (anito-cel), aimed at treating patients with relapsed/refractory multiple myeloma (r/r MM) [2] Industry Insights - The article highlights the importance of deep-dive analysis in the pharmaceutical sector, particularly for investors interested in biotech companies [2]